Coherus Biosciences | CHRS - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Baxter International USD 2.02B 51M 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
Fujifilm JPY 160.88B 906M 2025-09
Gilead Sciences USD 7.56B 234M 2025-12
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
Merck USD 5.33B 9.24B 2026-03
Myriad Genetics USD 124.4M 25.2M 2026-03
Pacira USD 144.31M 14.24M 2026-03
Perrigo USD 531.6M 99.5M 2025-12
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03
Xencor USD 14.17M 39.9M 2026-03
Zoetis USD 1.94B 369M 2026-03